Alpha Rising spent time with Thrive Global founder & CEO Arianna Huffington to talk about why corporations need to address burnout and stress if they want to succeed and why Amazon's Jeff Bezos agrees. Watch!
GE has restated its financials for the past two years, faces a massive $31 billion pension deficit, has liquidity concerns rising from the long-term health obligations of its largely divested GE Capital unit and will likely revise earnings guidance down for the year. Investors probably can't handle much more.
Ultragenyx scored its second FDA drug approval in six months. The orphan disease specialist also picked up its second Rare Pediatric Disease Priority Review Voucher; its first sold for $130 million.
Abbott's Freestyle Libre in September secured FDA approval and in January, the company said the device had received reimbursement from the Centers for Medicare & Medicaid Services.
Jim Cramer and our other experts discuss Netflix and the FANGS, stock picking rewarded, and a way to hide from political risk.
The company's underwriting margins and traditional health insurance business are key areas to watch, according to BMO Capital Markets' Matthew Borsch.
The drugmakers on April 16 released data from their respective studies at the Association for Cancer Research's annual meeting in Chicago.
Shire will sell its oncology business to France's Servier for around $2.4 billion as it contemplates a possible $50 billion takeover from Japan's Takeda Pharmaceutical Co.
Deals in biopharma slowed in 2017 for the third consecutive year. According to Intec Pharma CEO Jeffrey Meckler, just because volume is down doesn't mean it's out.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.